Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Φλώρα Ζαγουρή, Αναπληρώτρια καθηγήτρια, Ιατρική σχολή, ΕΚΠΑ
Μαρία Γαβριατοπούλου, Επίκουρη Καθηγήτρια, Ιατρική σχολή, ΕΚΠΑ
Ευάγγελος Τέρπος, Καθηγητής, Ιατρική σχολή, ΕΚΠΑ
Original Title:
Αναστολείς PD-1/PD-L1 στην θεραπεία των ασθενών με προχωρημένο/μεταστατικό ή υποτροπιάζοντα καρκίνο του τραχήλου της μήτρας
Translated title:
PD1/PD-L1 inhibitors for advanced or recurrent cervical cancer
Summary:
Cervical cancer consists a major global public health issue, accounted for approximately 311.000 deaths every year. Despite the comprehensive cervical cancer control including primary prevention and secondary prevention, cervical cancer remains the fourth most common cancer in women worldwide and the second in developing countries. Almost half of the women are diagnosed at an advanced or metastatic stage of disease. The standard treatment for recurrent/metastatic cervical cancer is a combination of paclitaxel and cisplatin or paclitaxel and cisplatin and bevacizumab, associated with a median survival of one to one and a half years respectively. Taking into consideration that cervical cancer concerns young women, there is an urgent need for the discovery of new efficient treatments.
Objectives: This systematic review aims to evaluate the efficacy and safety of an emerging group of agents, PD-1/PD-L1 inhibitors, in reccurent/metastatic cervical cancer patients. Eligible articles were identified by a search of existing literature for the period 01/01/2000–28/02/2021. This study was performed in accordance with PRISMA guidelines and a specified algorithm was used in identifying eligible studies. Selection criteria: All phase I/II clinical trials evaluating the efficacy and safety of PD-1/PD-L1 inhibitors in recurrent/advanced/metastatic cervical cancer patients. Data collection: Overall, 10 phase I/II clinical trials were retrieved of which four studies explored the efficacy and safety of pembrolizumab, three studies of nivolumab, one of cemiplimab, one of atezolizumab, one of durvalumab in recurrent/advanved/metastatic cervical cancer. Conclusions: Pembolizumab exhibited promising results in terms of safety and efficacy as also did nivolumab. Patients under cemiplimab treatment developed more adverse events compared with other agents and low response to therapy. Atezolizumab could not meet the expected efficacy leading in zero response. Durvalumab has a manageable safety profile with promising preliminary results in terms of efficacy.
Main subject category:
Health Sciences
Keywords:
PD-1/PD-L1 Inhibitors, Recurrent, Metastatic, Cervical, Cancer
